A conference call will be held at 3:30 p.m. Friday to review the ORION-1 Phase II study of inclisiran, the Medicines Co.’s PCSK9 synthesis inhibitor.
The call will include some of the company’s management and product teams, as well of members of its advisory board, who will review the full safety and efficacy data from the study. The call will also allow people to have the chance to hear about the six- to nine-month followup for all patients in the study.
The conference call may be accessed by calling 877-359-9508 for people in the United States and Canada or 224-357-2393 for international callers. The conference ID is 60380330. The live webcast can be accessed on The Medicines Co.'s website.
A replay of the conference call will be available for approximately one week. The replay can be accessed at 855-859-2056 for U.S. and Canadian callers or 404-537-3406 for international callers. The conference ID is 60380330. A replay of the webcast will also be available.
Conference call to review study of inclisiran
Organizations in this Story
Want to get notified whenever we write about The Medicines Company ?
Next time we write about The Medicines Company, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts